



HHS Public Access

Author manuscript

Cancer Cell. Author manuscript; available in PMC 2019 October 08.

Published in final edited form as:

Cancer Cell. 2018 October 08; 34(4): 690. doi:10.1016/j.ccell.2018.09.008.

Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies

Roberta Zappasodi, Taha Merghoub*, and Jedd D. Wolchok*

After publication of the original article, the authors expressed the interest of disclosing all their interactions with industry, although not directly relevant to the published work, in the spirit of full transparency. The updated Declaration of Interests disclosure is reported here and in the online version of the paper. The authors apologize for any inconvenience.

*Correspondence: merghout@mskcc.org (T.M.), wolchokj@mskcc.org (J.D.W.).

DECLARATION OF INTERESTS

J.D.W. is a paid consultant to Advaxis, Bristol-Myers Squibb, Merck, Medimmune, Celgene, and Genentech and receives research funding from Bristol-Myers Squibb, Merck, Genentech, and Medimmune and honoraria from Ono Pharmaceuticals. J.D.W. is a co-founder and paid consultant and reports stock option ownership in Potenza Therapeutics, Tizona Therapeutics, and Imvaq. J.D.W. is a paid consultant and reports stock option ownership in Beigene and Apricity. J.D.W. is a paid consultant to Surface Oncology, Polaris, Polynoma, Array, Ascentage, Puretech, Chugai, FStar, Amgen, Sellas Life Sciences, Seramatrix, Neon, Eli Lilly, Psioxus, Syndax, Recepta, Amgen, and Puretech and reports stock option ownership in Adaptive Biotech. T.M. is a co-founder of Imvaq.